


PHARMACEUTICAL 2021

Cellectar Biosciences Inc. Rank 117 of 409





PHARMACEUTICAL 2021

Cellectar Biosciences Inc. Rank 117 of 409

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 268% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Revenues, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -3.2%, being 351% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 57,940 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 3,563 |
| Liabilities, Non-Current | 302 |
| Other Assets | 364 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 196 |
| Property and Equipment | 356 |
| Research and Development | 10,141 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 5,150 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 58,659 |
| Liabilities | 3,865 |
| Expenses | 15,290 |
| Stockholders Equity | 54,795 |
| Net Income | -15,094 |
| Comprehensive Net Income | -15,094 |
| Economic Capital Ratio | -3.2% |